Mendel.ai, a San Francisco, CA-based developer of an artificial intelligence engine that enables doctors and patients to quickly find the best diagnostic and treatment methods available for their patients’ medical conditions, raised $2m in seed funding.
The round was co-led by DCM Ventures and Bootstrap Labs with participation from Launch Capital, DeNa Strategic Investments and Advisors Fund’s Mark Goldstein.
The company intends to use the funds to continue to develop the paltform.
Led by Dr. Karim Galil, founder, Mendel.ai uses deep learning technology to sift through unstructured data in medical literature as well as patient health records, in order to suggest evidence-based treatment options and to continuously update the results whenever a new matching trial or treatment emerges. The company, which is currently focused on oncology and cancer patient populations, is also its first integration with the Comprehensive Blood & Cancer Center (CBCC) in Bakersfield, California. The integration and Mendel.ai’s artificial intelligence will allow the Center’s doctors to quickly and easily match their patients with available clinical trials in minutes instead of days or weeks.